February 21, 2023 10:48 AM ESTUpdated February 24, 04:15 AM
FDA+

Al­ny­lam gets an ad­comm for On­pat­tro treat­ment in AT­TR amy­loi­do­sis

Tyler Patchen

News Reporter

Al­ny­lam Phar­ma­ceu­ti­cals is hop­ing its lat­est round of da­ta for On­pat­tro’s treat­ment of AT­TR is enough to sat­is­fy the FDA. But they’ll have to make …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times